Multimodality Imaging for Cardiotoxicity: State of the Art and Future Perspectives.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
23
11
2021
accepted:
13
04
2022
pubmed:
7
5
2022
medline:
12
10
2022
entrez:
6
5
2022
Statut:
epublish
Résumé
Modern cancer therapies have significantly improved survival leading to a growing population of cancer survivors. Similarly, both conventional and newer treatments are associated with a spectrum of cardiovascular disorders with potential long-term sequelae. Prompt detection and treatment of these complications is, therefore, pivotal to enable healthy survivorship and reduce cardiovascular morbidity. Advanced multimodality imaging is a valuable tool for stratifying patient risk, identifying cardiovascular toxicity during and after therapy, and predicting recovery. This review summarizes the potential cardiotoxic complications of anticancer therapies and the multimodality approaches available in each case with special focus on newer techniques and the added value of biomarkers ultimately leading to earlier diagnosis and better prognostication.
Identifiants
pubmed: 35522143
doi: 10.1097/FJC.0000000000001281
pii: 00005344-202210000-00010
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-561Subventions
Organisme : British Heart Foundation
ID : FS/CRTF/21/24134
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. New Engl J Med. 2016;375:1457–1467.
Yeh ET, Chang HM. Oncocardiology—past, present, and future: a review. JAMA Cardiol. 2016;1:1066–1072.
Bannister C, Cannata A, Bromage D, et al. Cardiotoxicity of chemotherapeutic drugs: an update and future perspectives. J Cardiovasc Pharmacol. 2022 [epub ahead of print].
Ware JS, Li J, Mazaika E, et al.; IMAC-2 and IPAC Investigators. Shared genetic predisposition in peripartum and dilated cardiomyopathies. New Engl J Med. 2016;374:233–241.
Artico J, Merlo M, Delcaro G, et al. Lymphocytic myocarditis: a genetically predisposed disease? J Am Coll Cardiol. 2020;75:3098–3100.
Cannatà A, Merlo M, Dal Ferro M, et al. Association of titin variations with late-onset dilated cardiomyopathy. JAMA Cardiol. 2022;7:371–377.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768–2801.
Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27:911–939.
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171–190.
Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society. Eur J Heart Fail. 2020;22:1945–1960.
Saunderson CE, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021;22:383–396.
Castellano IA, Nicol ED, Bull RK, et al. A prospective national survey of coronary CT angiography radiation doses in the United Kingdom. J Cardiovasc Comput Tomogr. 2017;11:268–273.
Biersmith MA, Tong MS, Guha A, et al. Multimodality cardiac imaging in the era of emerging cancer therapies. J Am Heart Assoc. 2020;9:e013755.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36:2921–2964.
Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-oncology services: rationale, organization, and implementatio: a report from the ESC Cardio-Oncology council. Eur Heart J. 2019;40:1756–1763.
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911.
Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21:v277–v282.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019;74:e177–e232.
Esmaeilzadeh M, Urzua Fresno CM, Somerset E, et al. A combined echocardiography approach for the diagnosis of cancer therapy–related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol. 2022;7:330–340.
Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77–84.
Otterstad JE. Measuring left ventricular volume and ejection fraction with the biplane Simpson's method. Heart. 2020;88:559–560.
Palaskas N, Lopez-Mattei J. Cancer therapy cardiotoxicity detection: understanding the limitations of cardiac imaging. Heart. 2020;106:791–792.
Shiota T, McCarthy PM, White RD, et al. Initial clinical experience of real-time three-dimensional echocardiography in patients with ischemic and idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;84:1068–1073.
Jenkins C, Leano R, Chan J, et al. Reconstructed versus real-time 3-dimensional echocardiography: comparison with magnetic resonance imaging. J Am Soc Echocardiogr. 2007;20:862–868.
Corsi C, Lang RM, Veronesi F, et al. Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images. Circulation. 2005;112:1161–1170.
Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28:3429–3436.
Dobson R, Ghosh AK, Ky B, et al. British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Res Pract. 2021;8:G1–G18.
Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2:356–364.
Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent. J Am Coll Cardiol. 2008;51:1704–1706.
Anantharam B, Chahal N, Chelliah R, et al. Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin. Am J Cardiol. 2009;104:14–18.
Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493–498.
Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596–603.
Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor iipositive breast cancer treated with ad. J Am Coll Cardiol. 2011;57:2263–2270.
Poterucha JT, Kutty S, Lindquist RK, et al. Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr. 2012;25:733–740.
Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18:930–936.
Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77:392–401.
Thomson HL, Basmadjian AJ, Rainbird AJ, et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. J Am Coll Cardiol. 2001;38:867–875.
Malm S, Frigstad S, Sagberg E, et al. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging. J Am Coll Cardiol. 2004;44:1030–1035.
Yu EH, Sloggett CE, Iwanochko RM, et al. Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients. J Am Soc Echocardiogr. 2000;13:216–224.
Nahar T, Croft L, Shapiro R, et al. Comparison of four echocardiographic techniques for measuring left ventricular ejection fraction. Am J Cardiol. 2000;86:1358–1362.
Hundley WG, Kizilbash AM, Afridi I, et al. Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. J Am Coll Cardiol. 1998;32:1426–1432.
Mulvagh SL, Rakowski H, Vannan MA, et al. American society of echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21:1179–2201.
Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidence-based recommendations by European association of echocardiography. Eur J Echocardiogr. 2009;10:194–212.
Larsson MK, Silva Cda, Gunyeli E, et al. The potential clinical value of contrast-enhanced echocardiography beyond current recommendations. Cardiovasc Ultrasound. 2016;14:2.
Bhattacharyya S, Khattar R, Senior R. Characterisation of intra-cardiac masses by myocardial contrast echocardiography. Int J Cardiol. 2013;163:e11–e13.
Ong G, Brezden-Masley C, Dhir V, et al. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol. 2018;261:228–233.
Jolly MP, Jordan JH, Melendez GC, et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson. 2017;19:59.
Barbosa MF, Fusco DR, Gaiolla RD, et al. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines. BMC Cardiovasc Disord. 2021;21:170.
MyoStrain. CMR for the Detection of Cardiotoxicity (Prefect). Available at: https://clinicaltrials.gov/ct2/show/NCT03543228 . Accessed April 1, 2022.
Steen H, Montenbruck M, Gerzak B, et al. Cardiotoxicity during cancer treatment causes more regional than global dysfunction: the prefect study. J Am Coll Cardiol. 2020;75:1824.
Giusca S, Korosoglou G, Montenbruck M, et al. Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 Years of follow-up. Circ Cardiovasc Imaging 2021;14:10.
Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013;111:717–722.
Muehlberg F, Funk S, Zange L, et al. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail. 2018;5:620–629.
Ylanen K, Poutanen T, Savikurki-Heikkila P, et al. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013;61:1539–1547.
Thavendiranathan P, Wintersperger BJ, Flamm SD, et al. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6:1080–1091.
Ferreira VM, Piechnik SK, Dall'Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.
Jordan JH, Vasu S, Morgan TM, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016;9:e004325.
Tham EB, Haykowsky MJ, Chow K, et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson. 2013;15:48.
Altaha MA, Nolan M, Marwick TH, et al. Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy?: impact of temporal and observer variability. JACC Cardiovasc Imaging. 2020;13:951–962.
Haslbauer JD, Lindner S, Valbuena-Lopez S, et al. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol. 2019;275:179–186.
Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73:779–791.
Maffei E, Messalli G, Martini C, et al. Left and right ventricle assessment with Cardiac CT: validation study vs. Cardiac MR. Eur Radiol. 2012;22:1041–1049.
Makavos G, Ikonomidis I, Palios J, et al. Cardiac imaging in cardiotoxicity: a focus on clinical practice. Heart Fail Rev. 2021;26:1175–1187.
Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–3916.
Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Translational Res. 2020;13:431–450.
Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710–715.
Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522.
Zardavas D, Suter TM, Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study ca. J Clin Oncol. 2017;35:878–884.
Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011;105:1663–1668.
Wieshammer S, Dreyhaupt J, Müller D, et al. Limitations of N-terminal pro-B-type natriuretic peptide in the diagnosis of heart disease among cancer patients who present with cardiac or pulmonary symptoms. Oncology. 2016;90:143–150.
Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–1410.
Palumbo I, Palumbo B, Fravolini ML, et al. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: a prospective study. Breast. 2016;25:45–50.
Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2022;43:1687–1690.
Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134:291–298.
Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445.
Seraphim A, Westwood M, Bhuva AN, et al. Advanced imaging modalities to monitor for cardiotoxicity. Curr Treat Options Oncol. 2019;20:73.
Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. 2019;139:e579–e602.
Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299–2311.
Kiaos A, Tziatzios I, Hadjimiltiades S, et al. Diagnostic performance of stress perfusion cardiac magnetic resonance for the detection of coronary artery disease: a systematic review and meta-analysis. Int J Cardiol. 2018;252:229–233.
Bazoukis G, Papadatos SS, Michelongona A, et al. Contemporary role of cardiac magnetic resonance in the management of patients with suspected or known coronary artery disease. Medicina (Kaunas). 2021;57:649.
Vágó H, Szabó L, Dohy Z, et al. Early cardiac magnetic resonance imaging in troponin-positive acute chest pain and non-obstructed coronary arteries. Heart. 2020;106:992–1000.
Lancellotti P, Nkomo VT, Badano LP, et al.; European Society of Cardiology Working Groups on Nuclear C, Cardiac Computed T, Cardiovascular Magnetic R, American Society of Nuclear C, Society for Cardiovascular Magnetic R, Society of Cardiovascular Computed T. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the American society of echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721–740.
Celutkiene J, Pudil R, Lopez-Fernandez T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the Eur. Eur J Heart Fail. 2020;22:1504–1524.
Celeng C, Leiner T, Maurovich-Horvat P, et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis. JACC Cardiovasc Imaging. 2019;12:1316–1325.
Anastasius M, Maggiore P, Huang A, et al. The clinical utility of FFRCT stratified by age. J Cardiovasc Comput Tomogr. 2021;15:121–128.
Bourque JM, Beller GA. Stress myocardial perfusion imaging for assessing prognosis: an update. JACC Cardiovasc Imaging. 2011;4:1305–1319.
Rischpler C, Totzeck M. Are you stressed? J Nucl Cardiol. 2019;26:1898–1900.
Gayed IW, Liu HH, Yusuf SW, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med. 2006;47:1756–1762.
Löffler AI, Bourque JM. Coronary microvascular dysfunction, microvascular angina, and management. Curr Cardiol Rep. 2016;18:1.
Żyromska A, Małkowski B, Wiśniewski T, et al. 15 O-H 2 O PET/CT as a tool for the quantitative assessment of early post-radiotherapy changes of heart perfusion in breast carcinoma patients. Br J Radiol. 2018;91:20170653.
Park KC, Gaze DC, Collinson PO, et al. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;13:1708–1718.
Myhre PL, O'Meara E, Claggett BL, et al. Cardiac troponin I and risk of cardiac events in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2018;11:e005312.
Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809–816.
Blaes AH, Rehman A, Vock DM, et al. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manage. 2015;11:591–594.
Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. 2017;24:774–782.
Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–1764.
Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75:467–478.
Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158–3176.
Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41:1733–1743.
Si-Mohamed SA, Restier LM, Branchu A, et al. Diagnostic performance of extracellular volume quantified by dual-layer dual-energy CT for detection of acute myocarditis. J Clin Med. 2021;10:3286.
Nensa F, Kloth J, Tezgah E, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol. 2018;25:785–794.
Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80–91.
Boughdad S, Latifyan S, Fenwick C, et al. 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer 2021;9:e003594.
Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099–3108.
Cammann VL, Sarcon A, Ding KJ, et al. Clinical features and outcomes of patients with malignancy and takotsubo syndrome: observations from the international takotsubo registry. J Am Heart Assoc. 2019;8:e010881.
Desai A, Noor A, Joshi S, et al. Takotsubo cardiomyopathy in cancer patients. Cardiooncology. 2019;5:7.
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (Part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39:2047–2062.
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39:2032–2046.
Citro R, Okura H, Ghadri JR, et al. Multimodality imaging in takotsubo syndrome: a joint consensus document of the European Association of Cardiovascular Imaging (EACVI) and the Japanese Society of Echocardiography (JSE). J Echocardiogr. 2020;18:199–224.
Pelliccia F, Pasceri V, Patti G, et al. Long-term prognosis and outcome predictors in takotsubo syndrome: a systematic review and meta-regression study. JACC Heart Fail. 2019;7:143–154.
Plácido R, Cunha Lopes B, Almeida AG, et al. The role of cardiovascular magnetic resonance in takotsubo syndrome. J Cardiovasc Magn Reson. 2017;18:68.
Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865–1870.
Aikawa Y, Noguchi T, Morita Y, et al. Clinical impact of native T1 mapping for detecting myocardial impairment in takotsubo cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2019;20:1147–1155.
Haghi D, Athanasiadis A, Papavassiliu T, et al. Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J. 2006;27:2433–2439.
Villarroel AH, Vitola Jv, Stier AL, et al. Takotsubo or stress cardiomyopathy: role of nuclear cardiology using (123)I-MIBG. Expert Rev Cardiovasc Ther. 2009;7:847–852.
Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:76–92.
Rosmini S, Seraphim A, Knott K, et al. Non-invasive characterization of pleural and pericardial effusions using T1 mapping by magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2021 [epub ahead of print].
Taylor AM, Dymarkowski S, Verbeken EK, et al. Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur Radiol. 2006;16:569–574.
Francone M, Dymarkowski S, Kalantzi M, et al. Real-time cine MRI of ventricular septal motion: a novel approach to assess ventricular coupling. J Magn Reson Imaging. 2005;21:305–309.
Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation. 2003;108:1852–1857.
Alter P, Figiel JH, Rupp TP, et al. MR, CT, and PET imaging in pericardial disease. Heart Fail Rev. 2013;18:289–306.
Çetin MS, Çetin EH, Özdemir M, et al. Effectiveness of computed tomography attenuation values in characterization of pericardial effusion. Anatolian J Cardiol. 2017;17:322–327.
Bhargava P, Glass E, Brown J, et al. FDG PET in primary effusion lymphoma (PEL) of the pericardium. Clin Nucl Med. 2006;31:18–19.
Kircher M, Lapa C. Novel noninvasive nuclear medicine imaging techniques for cardiac inflammation. Curr Cardiovasc Imaging Rep. 2017;10:6.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30:303–371.
Baumgartner H, Falk V, Bax JJ, et al.; Group ESCSD. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.
Lancellotti P, Moura L, Pierard LA, et al. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307–332.
Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. J Am Med Assoc. 2003;290:2831–2837.
Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743–749.
Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart. 1996;75:591–595.
Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart. 2016:102:267–276.
Lancellotti P, Pellikka PA, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European association of cardiovascular imaging and the American society of echocardiography. J Am Soc Echocardiogr. 2017;30:101–138.
Lombardi M. The EACVI Textbook of Cardiovascular Magnetic resonance. Oxford, United Kingdom; Oxford University Press; 2018.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2786.
Kamdar AR, Meadows TA, Roselli EE, et al. Multidetector computed tomographic angiography in planning of reoperative cardiothoracic surgery. Ann Thorac Surg. 2008;85:1239–1245.
Kestler M, Muñoz P, Rodríguez-Créixems M, et al. Role of 18F-FDG PET in patients with infectious endocarditis. J Nucl Med. 2014;55:1093–1098.
Negishi T, Thavendiranathan P, Negishi K, et al. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging 2018;11:1098–1105.
Rider OJ, Apps A, Miller JJ, et al. Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI. Circ Res. 2020;126:725–736.
Khalique Z, Ferreira PF, Scott AD, et al. Diffusion tensor cardiovascular magnetic resonance imaging: a clinical perspective. JACC: Cardiovasc Imaging. 2020:13:1235–1255.